Q-omics provides the consensus-scored KCTD21 profile across patient tissues and cancer cell-line models. KCTD21 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, KCTD21 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, KCTD21 RNA expression shows 19,736 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight THCA, HNSC, and ACC as cancer lineages where KCTD21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCTD21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCTD21 survival associations across molecular data types. KCTD21 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCTD21 RNA expression–survival associations across cancer types. High KCTD21 expression shows unfavorable associations in KICH, MESO, SKCM and UCEC, but favorable associations in THCA and BRCA. The THCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify THCA as the clearest survival context for KCTD21 RNA expression.
This table summarizes KCTD21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for KCTD21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCTD21 shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, LIHC, LUAD and BRCA. The HNSC box plot shows higher KCTD21 RNA expression in tumor versus normal tissue (log2 FC = +0.631, t-test p < 0.001).
This table shows molecular features associated with KCTD21 in patient tissues and cancer cell lines. In patient samples, KCTD21 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KCTD21 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
